The Indian pharmaceutical market continued rising in April 2025, achieving a strong annual growth of 7.8%, with total sales reaching a remarkable Rs 19,711 crore.
According to a report by Pharmatrack, the sector recorded an impressive Rs 1,424 crore in additional sales this month, highlighting its continued resilience and strong demand.
The report attributed the growth primarily to price-led expansion, as well as the impact of new product introductions (NIS). On a moving annual total (MAT) basis, the industry surged to Rs 2,27,361 crore, reflecting an 8.3 per cent increase year-on-year and a healthy 10.3 per cent Compound annual growth rate (CAGR). These figures highlight the sector’s long-term growth potential and strong position in the market.
Therapeutic segments such as cardiac, neuro/CNS, blood-related, anti-neoplastics, ophthalmology/otology, and urology were major contributors to the momentum in April, as the importance of speciality and chronic therapies continues to grow, driving the market's expansion.
Despite modest volume growth of just 0.4 per cent, the industry’s effective pricing strategies enabled it to manage cost pressures and maintain topline growth. Among the therapy areas, cardiac and anti-Infectives saw major volume boosts in April because of sustained demand in chronic disease management and acute care needs, respectively.
The cardiac therapy segment, in particular, showed strong performance, driven by continuous demand for anti-hypertensives, lipid lowering agents, and heart failure therapies. Meanwhile, the anti-infectives sector rose from seasonal infections and localised outbreaks, leading to a noticeable volume surge.
From a pricing perspective, Respiratory therapy led the charge with a 6.6 per cent price increase, followed by Cardiac and Gastrointestinal therapies, reflecting pricing dynamics in high-demand categories.
The report also highlighted the success of stomatologicals, which emerged as a standout in new product performance, registering a 7.7 per cent growth. This growth was largely driven by launches in specialised care areas where competition remains relatively low and demand is evolving.
According to a report by Pharmatrack, the sector recorded an impressive Rs 1,424 crore in additional sales this month, highlighting its continued resilience and strong demand.
The report attributed the growth primarily to price-led expansion, as well as the impact of new product introductions (NIS). On a moving annual total (MAT) basis, the industry surged to Rs 2,27,361 crore, reflecting an 8.3 per cent increase year-on-year and a healthy 10.3 per cent Compound annual growth rate (CAGR). These figures highlight the sector’s long-term growth potential and strong position in the market.
Therapeutic segments such as cardiac, neuro/CNS, blood-related, anti-neoplastics, ophthalmology/otology, and urology were major contributors to the momentum in April, as the importance of speciality and chronic therapies continues to grow, driving the market's expansion.
Despite modest volume growth of just 0.4 per cent, the industry’s effective pricing strategies enabled it to manage cost pressures and maintain topline growth. Among the therapy areas, cardiac and anti-Infectives saw major volume boosts in April because of sustained demand in chronic disease management and acute care needs, respectively.
The cardiac therapy segment, in particular, showed strong performance, driven by continuous demand for anti-hypertensives, lipid lowering agents, and heart failure therapies. Meanwhile, the anti-infectives sector rose from seasonal infections and localised outbreaks, leading to a noticeable volume surge.
From a pricing perspective, Respiratory therapy led the charge with a 6.6 per cent price increase, followed by Cardiac and Gastrointestinal therapies, reflecting pricing dynamics in high-demand categories.
The report also highlighted the success of stomatologicals, which emerged as a standout in new product performance, registering a 7.7 per cent growth. This growth was largely driven by launches in specialised care areas where competition remains relatively low and demand is evolving.
You may also like
India, Pakistan agree to unconditional ceasefire; Indus Water Treaty to remain in abeyance
After ceasefire, Congress demands all-party meeting and special Parliament session
Tom Brady shows his class with Rory McIlroy comments after getting his 'butt kicked'
Bihar: Jan Suraaj postpones all political activities amid India-Pakistan tension
Arsenal make contract decision as Andrea Berta puts summer transfer plans in motion
